Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 plus camrelizumab in previously treated advanced primary hepatocellular carcinoma
CTR20233149Phase 2Active
- Sponsor
- Sinopharm CNBG-Virogin Biotech
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VG161, camrelizumab in hepatocellular carcinoma (HCC), sponsored by Sinopharm CNBG-Virogin Biotech. Started Dec 2023; status: active.
02
Drugs
VG161camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20233149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233149.